Literature DB >> 19837053

Major depression, cognitive dysfunction and Alzheimer's disease: is there a link?

Annerieke S R Sierksma1, Daniel L A van den Hove, Harry W M Steinbusch, Jos Prickaerts.   

Abstract

Major depression (MD) is a severe mental disorder characterized by alterations in mood and cognition, with disease severity correlating inversely with cognition scores. Neuropathology can be found abundantly in the limbic system, which is thought to regulate affect, attention and memory. Hypothalamic-pituitary-adrenal (HPA) axis overdrive, as well as decreased serotonin levels, have often been implicated in the pathogenesis of this illness. Interestingly, there is substantial interaction between these two systems, with receptors of one system influencing the function of the other. This results in impaired neural networks, which give rise to the wide range of depressive symptoms. Recently, it has been implied that MD could serve as a risk factor for developing Alzheimer's disease (AD), with patients suffering from lifetime depression having a twofold higher chance of developing AD and exhibiting more AD-related neuropathology. Modifications in the HPA-axis and the serotonergic system may contribute to the development of cognitive decline and eventually AD. These two systems may therefore be involved in the pathogenesis of both illnesses and could provide a link between MD and AD. Obtaining more knowledge on their interactive role in the relation between MD and AD may eventually aid in the development of more effective treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837053     DOI: 10.1016/j.ejphar.2009.10.021

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

1.  Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.

Authors:  Mitchell K P Lai; Shirley W Tsang; Margaret M Esiri; Paul T Francis; Peter T-H Wong; Christopher P Chen
Journal:  Psychopharmacology (Berl)       Date:  2010-07-13       Impact factor: 4.530

2.  Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens.

Authors:  Tonita E Wroolie; Heather A Kenna; Katherine E Williams; Bevin N Powers; Megan Holcomb; Anna Khaylis; Natalie L Rasgon
Journal:  Am J Geriatr Psychiatry       Date:  2011-09       Impact factor: 4.105

3.  NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor.

Authors:  Samer Abdul-Hay; Isaac T Schiefer; R Esala P Chandrasena; Min Li; Ramy Abdelhamid; Yue-Ting Wang; Ehsan Tavassoli; Bradley Michalsen; Rezene T Asghodom; Jia Luo; Gregory R J Thatcher
Journal:  ACS Med Chem Lett       Date:  2011-09-08       Impact factor: 4.345

Review 4.  Depression associated with dementia.

Authors:  H Gutzmann; A Qazi
Journal:  Z Gerontol Geriatr       Date:  2015-05-12       Impact factor: 1.281

Review 5.  [Late-onset depression : Pathophysiology, diagnostics and treatment].

Authors:  S Notzon; J Alferink; V Arolt
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

Review 6.  Depression and risk of developing dementia.

Authors:  Amy L Byers; Kristine Yaffe
Journal:  Nat Rev Neurol       Date:  2011-05-03       Impact factor: 42.937

Review 7.  How Studies of the Serotonin System in Macaque Models of Menopause Relate to Alzheimer's Disease1.

Authors:  Cynthia L Bethea; Arubala P Reddy; Fernanda Lima Christian
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Gene-environment interaction research and transgenic mouse models of Alzheimer's disease.

Authors:  L Chouliaras; A S R Sierksma; G Kenis; J Prickaerts; M A M Lemmens; I Brasnjevic; E L van Donkelaar; P Martinez-Martinez; M Losen; M H De Baets; N Kholod; F van Leeuwen; P R Hof; J van Os; H W M Steinbusch; D L A van den Hove; B P F Rutten
Journal:  Int J Alzheimers Dis       Date:  2010-10-05

9.  Antidepressant-Like Effect of Ropren® in β-Amyloid-(25-35) Rat Model of Alzheimer's Disease with Altered Levels of Androgens.

Authors:  Vagif Soultanov; Julia Fedotova; Tamara Nikitina; Victor Roschin; Natalia Ordyan; Lucian Hritcu
Journal:  Mol Neurobiol       Date:  2016-03-19       Impact factor: 5.590

10.  A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression.

Authors:  Ulla Knorr; Maj Vinberg; Anders Gade; Per Winkel; Christian Gluud; Jørn Wetterslev; Ulrik Gether; Lars Kessing
Journal:  Ther Adv Psychopharmacol       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.